Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) and Envetec completed a joint feasibility pilot demonstrating closed-loop recycling of polystyrene Petri dishes into new manufacturing feedstock.
The study processed plated media as post-industrial material through Envetec's GENERATIONS chemical disinfection to produce clean polymer flakes, extruded into pellets and molded into Petri dish prototypes.
BD (NYSE: BDX) declared a quarterly cash dividend of $1.05 per common share, payable March 31, 2026, to holders of record on March 10, 2026, equal to an indicated annual dividend of $4.20 per share. The company has repurchased $250 million of BD stock to date in fiscal 2026. The board also authorized repurchases of up to 10 million additional shares of common stock, to be executed via open market purchases, privately negotiated transactions or other methods. Management will determine the timing, manner, number and value of repurchases at its discretion and subject to market, economic and business considerations.
BD (NYSE: BDX) will host an audio webcast at 8:00 a.m. ET on Monday, February 9, 2026 to discuss financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) and to provide an update on operations and strategy. Prior to the call, the company will issue a news release and presentation materials including summary financial information.
The live audio webcast and subsequent replay will be available at www.bd.com/investors.
BD (NYSE: BDX) set Feb 5, 2026 as the record date for the spin-off of its Biosciences & Diagnostic Solutions business and expects to combine the spun-off unit with Waters (NYSE: WAT) via a Reverse Morris Trust on Feb 9, 2026, subject to customary closing conditions.
Under the terms, BD will receive $4 billion cash, and BD shareholders will receive Waters common stock representing 39.2% of the combined company on a fully diluted basis; Waters shareholders will own 60.8%.
Shares will trade with due bills starting Feb 5 and trade ex-distribution after closing; BD received a favorable IRS private letter ruling.
Waters (NYSE: WAT) shareholders approved issuing Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) for the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with preliminary voting showing ~99% support.
Waters and BD received all required regulatory approvals and BD obtained a favorable IRS Private Letter Ruling on U.S. federal tax matters. The transaction is expected to close on February 9, 2026, subject to customary closing conditions. Waters will release Q4 2025 results and hold a conference call and webcast on February 9, 2026 at 8:30 a.m. ET; a replay will be available through at least March 9, 2026.
BD (NYSE: BDX) announced the global commercial release of BD Research Cloud 7.0 on January 23, 2026, introducing BD Horizon Panel Maker, an AI-powered tool for automated panel design to support immunology and cancer research.
The cloud-based platform supports collaboration, workflow streamlining and lab operations management, and the new AI tool generates optimized panel recommendations within seconds from custom inputs or curated validated databases. The release highlights integrated visualization features (comparison tables and complexity scores) and explicit support for imaging and spectral panel design with BD FACSDiscover instruments. BD Research Cloud 7.0 is commercially available at bdresearchcloud.com.
BD (NYSE:BDX) and Ypsomed are expanding their collaboration to develop a 5.5 mL BD Neopak™ XtraFlow™ glass prefillable syringe compatible with Ypsomed's YpsoMate® 5.5 autoinjector to support large‑volume, high‑viscosity subcutaneous biologics. The syringe uses an 8 mm needle and thinner cannulas to improve flow and reduce injection time. Syringe samples for feasibility studies and YpsoMate 5.5 platform updates are expected in mid‑2026.
BD (NYSE: BDX) received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System on January 15, 2026. The multi-modality biopsy system is designed to work across breast imaging platforms, offering adjustable vacuum strengths, a variable sample notch, 360° sampling, echogenic cutting cannula, illuminated sample container, and probe choices of 12G, 10G, and 7G. The system is expected to enter the market in early 2026, expanding BD's breast health portfolio to support earlier detection and diagnosis.
BD (NYSE: BDX) named Shawn Bevec senior vice president of investor relations, effective Jan. 20, 2026. Bevec will lead investor communications and report to interim CFO Vitor Roque until a new leader is appointed. He joins from Quest Diagnostics, where he served as vice president of investor relations, and previously worked as a sell‑side analyst at Deutsche Bank and Susquehanna International Group and in R&D roles at Pfizer and Johnson & Johnson. Bevec holds a B.S. in Chemistry from the University of Arizona and an MBA from NYU Stern.
BD (NYSE: BDX) announced a $110 million investment to expand production of BD Neopak™ Glass Prefillable Syringes in Columbus, Nebraska, creating about 120 jobs and strengthening U.S. pharmaceutical supply chains.
The plan allocates $100 million for Neopak syringe production with supply expected in mid-2026 and $10 million to enhance cannula manufacturing; it follows a prior >$35 million Columbus expansion and sits within a broader pledge to invest $2.5 billion in U.S. manufacturing over five years.